Immutep Ltd (AX:IMM) has reported encouraging progress from its in-house and partnered programmes over the past few months. Interim data from the TACTI-mel combo study included a 61% response rate from the start of the Keytruda monotherapy screening period among subjects who went on to receive eftilagimod alpha (efti or IMP321) combo therapy. Partners GSK and Novartis are progressing their in-licensed LAG-3 programmes into Phase II or proof of concept studies, which increases the likelihood that these programmes will return significant value to Immutep. Our valuation has increased to A$510m or A$0.17/share (from A$439m or A$0.14/share).
Encouraging TACTI-mel data – update due November
Patients in the first three TACTI-mel cohorts showed a 33% response rate from the start of efti/Keytruda combo therapy and 61% from the start of the Keytruda monotherapy screening period. The six-patient additional cohort is fully recruited; treatment with efti started at the same time as Keytruda (vs 12 weeks after the start of Keytruda therapy in the first three cohorts). A data update is due in November.
To read the entire report Please click on the pdf File Below:
Which stock should you buy in your very next trade?
AI computing powers are changing the stock market. Investing.com's ProPicks AI includes 6 winning stock portfolios chosen by our advanced AI. In 2024 alone, ProPicks AI identified 2 stocks that surged over 150%, 4 additional stocks that leaped over 30%, and 3 more that climbed over 25%. Which stock will be the next to soar?
Unlock ProPicks AI